Equities analysts expect Quidel Co. (NASDAQ:QDEL) to report earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Quidel’s earnings. Quidel reported earnings of ($0.06) per share during the same quarter last year, which would indicate a negative year over year growth rate of 133.3%. The business is scheduled to issue its next quarterly earnings results on Wednesday, February 14th.
According to Zacks, analysts expect that Quidel will report full-year earnings of ($0.23) per share for the current financial year. For the next year, analysts anticipate that the company will report earnings of $1.24 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Quidel.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.21). Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The company had revenue of $50.89 million for the quarter, compared to the consensus estimate of $50.47 million. During the same quarter last year, the business posted $0.10 earnings per share. Quidel’s revenue was up 3.1% on a year-over-year basis.
Shares of Quidel (NASDAQ:QDEL) traded down $0.18 during trading hours on Friday, reaching $45.99. The company’s stock had a trading volume of 95,300 shares, compared to its average volume of 343,786. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. Quidel has a fifty-two week low of $18.25 and a fifty-two week high of $47.60. The company has a market cap of $1,560.00, a PE ratio of -287.44, a PEG ratio of 1.48 and a beta of 1.15.
In other news, Director Jack W. Schuler sold 4,000 shares of Quidel stock in a transaction on Friday, January 5th. The stock was sold at an average price of $47.02, for a total transaction of $188,080.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Ratan S. Borkar sold 29,880 shares of Quidel stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $45.15, for a total value of $1,349,082.00. Following the sale, the senior vice president now owns 20,253 shares in the company, valued at $914,422.95. The disclosure for this sale can be found here. Insiders have sold a total of 385,790 shares of company stock worth $15,760,155 over the last quarter. Company insiders own 22.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. Russell Investments Group Ltd. bought a new stake in shares of Quidel during the 2nd quarter worth $209,000. Schwab Charles Investment Management Inc. raised its stake in shares of Quidel by 45.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 174,788 shares of the company’s stock worth $4,744,000 after purchasing an additional 54,206 shares during the period. Legal & General Group Plc raised its stake in shares of Quidel by 4.0% during the 2nd quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock worth $197,000 after purchasing an additional 278 shares during the period. Prudential Financial Inc. bought a new stake in shares of Quidel during the 2nd quarter worth $2,399,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Quidel during the 2nd quarter worth $527,000. Institutional investors own 92.67% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Quidel Co. (QDEL) to Announce -$0.14 EPS” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/14/analysts-anticipate-quidel-co-qdel-to-announce-0-14-eps.html.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Quidel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quidel and related companies.